FB2001 placebo

DRUG4 trials

Sponsors

Frontier Biotechnologies Inc.

Conditions

COVID-19Covid19Mild to Moderate COVID-19

Phase 1

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

CompletedNCT04766931

Frontier Biotechnologies Inc.Covid19

Start: 2021-03-17End: 2022-08-12Updated: 2022-11-28

A Bridging Study of FB2001 in Healthy Subjects

CompletedNCT05197179

Frontier Biotechnologies Inc.COVID-19

Start: 2021-12-29End: 2022-06-02Updated: 2022-07-06

Phase 2

Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)

Frontier Biotechnologies Inc.COVID-19

Start: 2022-09-14End: 2023-12-31Target: 1188Updated: 2023-01-05

Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19

Frontier Biotechnologies Inc.Mild to Moderate COVID-19

Start: 2023-01-04End: 2023-12-31Target: 1336Updated: 2023-01-09

Related Papers

Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.

2025-01-011 citations

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.

2022-10-2927 citations